secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001104659-23-058085
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma Q1 net loss $4.0M; initiates Phase 1b for NXP800 in ovarian cancer
--------------------------------------------------------------------------------

- Cash $15.5M as of March 31, 2023 vs $20.0M at Dec 31, 2022; net loss $4.0M (Q1 2023) vs $2.9M (Q1 2022).
- Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer initiated; multicenter trial with GOG Foundation and ENGOT.
- IND for NXP900 pending; first-in-human trial expected shortly after IND becomes effective.
- Mayo Clinic investigators presented in-vivo PDX data at AACR showing NXP800 potential in cholangiocarcinoma.
- Company expects cash into H2 2024; R&D expenses $2.4M (up $0.6M YoY), G&A $1.7M (up $0.6M YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923058085/0001104659-23-058085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923058085/tm2315012d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-058085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer